scispace - formally typeset
Journal ArticleDOI

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

TLDR
Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
About
This article is published in The Lancet.The article was published on 2002-03-23. It has received 5380 citations till now. The article focuses on the topics: Angiotensin II & Atenolol.

read more

Citations
More filters
Journal ArticleDOI

Resistant Hypertension: A Review of Diagnosis and Management

TL;DR: Clinicians should exclude pseudoresistant hypertension, which results from nonadherence to medications or from elevated blood pressure related to the white coat syndrome, but in patients with truly resistant hypertension, thiazide diuretics, particularly chlorthalidone, should be considered as one of the initial agents.
Journal ArticleDOI

Heart rate, lifespan, and mortality risk

TL;DR: Future research is needed to determine whether deliberate cardiac slowing, through methods like lifestyle modification, pharmacological intervention, or medical devices, can decelerate biological clock of aging, reduce cardiovascular mortality and increase maximum lifespan in humans in general.
Journal ArticleDOI

Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation: The Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study

TL;DR: V visceral fat redistribution, liver fat accumulation, low-grade inflammation, and aggravated insulin resistance were demonstrated after hydrochlorothiazide but not candesartan treatment, which can partly explain the diabetogenic potential of thiazides.
Journal ArticleDOI

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions

TL;DR: A critical and comprehensive update of the current evidence for a cardiovascular disease (CVD) continuum based on the results of pathophysiological studies and the outcome of a broad range of clinical trials that have been performed in the past 15 years is presented.
Journal ArticleDOI

Antihypertensive Medications and the Risk of Incident Type 2 Diabetes

TL;DR: In this paper, the authors examined the association between the use of different classes of antihypertensive medications and the risk of incident type 2 diabetes and found that β-blocker and ACE inhibitors were associated with risk.
References
More filters
Journal ArticleDOI

Effects of an angiotensin-converting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

TL;DR: Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Journal ArticleDOI

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

TL;DR: Captopril and conventional treatment did not differ in efficacy in preventing cardiovascular morbidity and mortality and the difference in stroke risk was probably due to the lower levels of blood pressure obtained initially in previously treated patients randomised to conventional therapy.
Journal ArticleDOI

An updated coronary risk profile. A statement for health professionals.

TL;DR: Using a simple worksheet, a patient's 5- and 10-year CHD risks can be estimated using components of the profile selected because they are objective and strongly and independently related to CHD.
Journal ArticleDOI

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

TL;DR: Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
Related Papers (5)